AMIKACIN SULFATE INJECTION 250 MG
AMIKACIN (AMIKACIN SULFATE) : 250 MG · DIN 02486717 · OMEGA LABORATORIES LIMITED
Health Canada status: MARKETED
What is AMIKACIN SULFATE INJECTION?
AMIKACIN SULFATE INJECTION 250 MG contains AMIKACIN (AMIKACIN SULFATE) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02486717, held by OMEGA LABORATORIES LIMITED, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 31-Jul-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AMIKACIN SULFATE INJECTION used for?
Amikacin Sulfate Injection is indicated in the short - term treatment of serious infections due to susceptible strains of Pseudomonas species, Escherichia coli, Proteus species, Klebsiella - Enterobacter - Serratia species, Providencia species, Salmonella species, Citrobacter species and Staphylococcus aureus. Clinical effectiveness has been shown in bacteremia, septicemia (including neonatal sepsis), osteomyelitis, septic arthritis; respiratory tract, urinary tract, intra-abdominal (including peritonitis) infections and soft tissue abscesses.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02486717 |
|---|---|
| Brand name | AMIKACIN SULFATE INJECTION |
| Generic / active ingredient | AMIKACIN (AMIKACIN SULFATE) : 250 MG |
| Manufacturer | OMEGA LABORATORIES LIMITED |
| Strength | 250 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | J01GB06 AMIKACIN |
| AHFS class | 08:12.02 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Jul-2019 |
| Original market date | 2019-07-31 00:00:00 |
How is it stored and handled?
Store between 15 and 25 °C. Protect from light.
How is it supplied?
2 mL Flip-Off vials, boxes of 10
Is AMIKACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by OMEGA LABORATORIES LIMITED, last seen 12 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01GB06 AMIKACIN. 4 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02529459 |
| AMIKACIN SULFATE INJECTION USP | 250 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02242971 |
| AMIKACIN SULFATE INJECTION USP | 500 MG / 2 ML | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02481073 |
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | HIKMA CANADA LIMITED | CANCELLED POST MARKET | DIN 02525909 |
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | CANCELLED PRE MARKET | DIN 02539535 |
| AMIKIN | 250 MG | SOLUTION | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 00397415 |
| ERFA-AMIKACIN | 250 MG | SOLUTION | SEARCHLIGHT PHARMA INC | CANCELLED POST MARKET | DIN 02489147 |
| VPI-AMIKACIN | 500 MG / 2 ML | SOLUTION | VPI PHARMACEUTICALS INC | DORMANT | DIN 02506599 |
Who else supplies AMIKACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMIKACIN appears in 61 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.